Exclusive Summary

• As a classic long-acting oral antipsychotic, Penfluridol 20mg requires only once-weekly dosing, effectively resolving the clinical pain point of poor medication adherence in schizophrenia patients.
• Targeting over 24 million schizophrenia patients globally, this product operates in an uncrowded niche market, allowing it to efficiently fill regional supply gaps caused by the discontinuation of mature originator drugs.
• Supported by China's integrated API-to-formulation industry chain, the product offers significant cost advantages and comprehensive registration dossiers, making it optimal for distribution and public health tenders in emerging markets.